Effect of a Somatostatin Analogue on Trophic Hormone Levels in Acromegalic Patients with Elevated hGH after Adrenomectomy and Treatment with Bromocriptine

2009 ◽  
Vol 84 (05) ◽  
pp. 190-196 ◽  
Author(s):  
G. Szilágyi ◽  
G. Irsy ◽  
M. Góth ◽  
I. Szabolcs ◽  
D. Coy ◽  
...  
Keyword(s):  
Somatostatin Analogue ◽  
Hormone Levels ◽  
Trophic Hormone

Reduction of pituitary size by the somatostatin analogue SMS 201-995 in a patient with an islet cell tumour secreting growth hormone releasing factor

1986 ◽  
Vol 113 (1) ◽  
pp. 23-28 ◽  
Author(s):  
Darrell M. Wilson ◽  
Andrew R. Hoffman
Keyword(s):  
Growth Hormone ◽  
Islet Cell ◽  
Substantial Reduction ◽  
Good Control ◽  
Cell Tumour ◽  
Somatostatin Analogue ◽  
Pancreatic Islet Cell ◽  
Growth Hormone Releasing Factor ◽  
Hormone Levels ◽  
Islet Cell Tumour

Abstract. Acromegaly is rarely caused by the ectopic secretion of growth hormone releasing factor (GRF) from peripheral neuroendocrine tumours. We evaluated the ability of a recently developed somatostatin analogue (SMS 201-995, Sandoz) to reduce hormone levels and pituitary size in a young woman with acromegaly and Zollinger-Ellison syndrome secondary to a metastatic pancreatic islet cell tumour secreting GRF and gastrin. Gastrin, GRF, and growth hormone (GH) levels declined dramatically following the initiation of therapy with the analogue by continuous iv infusion. Although intermittent sc therapy was not effective in suppressing hormone levels, continuous sc infusion of SMS 201-995 has provided good control of both GRF and GH levels for nine months. Moreover, treatment with SMS 201-995 was associated with a substantial reduction in pituitary enlargement and an improvement in her gastric symptoms. Continuous sc infusion of SMS 201-995 may be useful in treating enlarged pituitaries resistant to other modes of therapy.

Effect of the Oestrus Cycle on Coxofemoral Joint Laxity

1997 ◽  
Vol 10 (02) ◽  
pp. 69-74 ◽  
Author(s):  
G. K. Smith ◽  
M. G. Conzemius ◽  
H. M. Saunders ◽  
C. M. Hill ◽  
T. P. Gregor ◽  
...  
Keyword(s):  
Prospective Study ◽  
Hip Dysplasia ◽  
Joint Laxity ◽  
Hormone Levels ◽  
Oestrus Cycle ◽  
Clinically Significant ◽  
A Prospective Study

SummaryA few investigations in the 1960’s were performed to document the effect of exogenous oestrogens on development of hip dysplasia. These projects concluded that oestrogen administration caused a significant increase in hip dysplasia. Additionally, the Orthopaedic Foundation for Animals (OFA) has recommended that bitches should not have hip evaluation for certification during oestrus, due to the possibility of increased coxofemoral joint laxity. The purpose of this project was to determine if physiological fluctuations of oestrogen and progesterone throughout the oestrus cycle significantly affected coxofemoral joint laxity. Nine bitches were evaluated through a single oestrus cycle. Although significant fluctuations of oestrogen and progesterone occurred throughout the phases of the oestrus cycle, neither statistically nor clinically significant changes in coxofemoral joint laxity were documented.A prospective study documented the effect of fluctuations of hormone levels throughout the oestrus cycle on coxofemoral joint laxity in nine dogs. Although oestrogen and progesterone levels changed significantly throughout the oestrus cycle, neither statistically nor clinically significant changes in hip laxity were observed.

THE EFFECT OF THE PROGESTOGEN ETHYNODIOL DIACETATE ON GLUCOSE, INSULIN, AND GROWTH HORMONE AFTER SIX MONTHS TREATMENT

1972 ◽  
Vol 70 (2) ◽  
pp. 373-384 ◽  
Author(s):  
W. N. Spellacy ◽  
W. C. Buhi ◽  
S. A. Birk
Keyword(s):  
Growth Hormone ◽  
Blood Glucose ◽  
Plasma Insulin ◽  
Tolerance Test ◽  
Metabolic Effects ◽  
Oral Glucose ◽  
Hormone Levels ◽  
Glucose Levels ◽  
Ethynodiol Diacetate ◽  
Tolerance Curve

ABSTRACT Seventy-one women were treated with a daily dose of 0.25 mg of the progestogen ethynodiol diacetate. They were all tested with a three-hour oral glucose tolerance test before beginning the steroid and then again during the sixth month of use. Measurements were made of blood glucose and plasma insulin and growth hormone levels. There was a significant elevation of the blood glucose levels after steroid treatment as well as a deterioration in the tolerance curve in 12.9% of the women. The plasma insulin values were also elevated after drug treatment whereas the fasting ambulatory growth hormone levels did not significantly change. There was a significant association between the changes in glucose and insulin levels and the subject's age, control weight, or weight gain during treatment. The importance of considering the metabolic effects of the progestogen component of oral contraceptives is stressed.

Sign in / Sign up

Export Citation Format

Share Document